BRD4抑制使弥漫性大B细胞淋巴瘤细胞对铁死亡敏感
研究筛选靶向表观遗传调节剂的化合物库以寻找铁死亡增敏药物,发现BET抑制剂可使生发中心B细胞样(GCB)亚型弥漫性大B细胞淋巴瘤(DLBCL)细胞对铁死亡诱导敏感。BET抑制剂与铁死亡诱导剂(如富马酸二甲酯或RSL3)联合在体外和体内协同杀伤DLBCL细胞,BRD4是铁死亡抑制蛋白1表达的关键调节因子。
要点
- BET抑制剂使GCB亚型DLBCL细胞对铁死亡诱导敏感。
- BET抑制剂与富马酸二甲酯或RSL3联合在体外和体内协同杀伤DLBCL细胞。
- BRD4是铁死亡抑制蛋白1表达的关键调节因子,保护GCB-DLBCL细胞免于铁死亡。
核心结论
- BRD4被鉴定为GCB-DLBCL中铁死亡抑制的重要参与者,为BET抑制剂联合铁死亡诱导剂作为DLBCL治疗新策略提供了依据。
研究设计与样本
- 研究筛选了靶向表观遗传调节剂的化合物库以鉴定铁死亡增敏药物,并在体外和体内评估了BET抑制剂与铁死亡诱导剂联合对DLBCL细胞的作用。
主要发现
- BET抑制剂使GCB亚型DLBCL细胞对铁死亡诱导敏感。
- BET抑制剂与富马酸二甲酯或RSL3联合在体外和体内协同杀伤DLBCL细胞。
- BRD4是铁死亡抑制蛋白1表达的关键调节因子,保护GCB-DLBCL细胞免于铁死亡。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma, is characterized by an aggressive clinical course. In approximately one-third of patients with DLBCL, first-line multiagent immunochemotherapy fails to produce a durable response. Molecular heterogeneity and apoptosis resistance pose major therapeutic challenges in DLBCL treatment. To circumvent apoptosis resistance, the induction of ferroptosis might represent a promising strategy for lymphoma therapy. In this study, a compound library, targeting epigenetic modulators, was screened to identify ferroptosis-sensitizing drugs. Strikingly, bromodomain and extra-terminal domain (BET) inhibitors sensitized cells of the germinal center B-cell-like (GCB) subtype of DLBCL to ferroptosis induction and the combination of BET inhibitors with ferroptosis inducers, such as dimethyl fumarate or RSL3, synergized in the killing of DLBCL cells in vitro and in vivo. On the molecular level, the BET protein BRD4 was found to be an essential regulator of ferroptosis suppressor protein 1 expression and thus to protect GCB-DLBCL cells from ferroptosis. Collectively, we identified and characterized BRD4 as an important player in ferroptosis suppression in GCB-DLBCL and provide a rationale for the combination of BET inhibitors with ferroptosis-inducing agents as a novel therapeutic approach for DLBCL treatment.
引用
- Schmitt A, Grimm M, Kreienkamp N, et al. BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis. Blood. 2023. PMID: 37294920. doi:10.1182/blood.2022019274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。